Brief: Resmed Q3 Adjusted EPS USD 2.86 Vs. IBES Estimate USD 2.8
30/04/2026 21:05
Apr 30 (Reuters) - Resmed Q3 revenue USD 1,400 million vs. IBES estimate USD 1,419 million. Q3 adjusted gross margin 62.8% Q3 EPS USD 2.74
Recent news on ResMed
See all newsCiti lifts ResMed's ASX-listed stock's target price after FX, valuation updates
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
Brief: Resmed - Enters Accelerated Share Repurchase Agreement To Repurchase $450 Million Of Common Stock - SEC Filing
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT